Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: EXC002
MIFTS: 41

Exocrine Pancreatic Insufficiency

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Exocrine Pancreatic Insufficiency

About this section

MalaCards integrated aliases for Exocrine Pancreatic Insufficiency:

Name: Exocrine Pancreatic Insufficiency 39 12 56 45 15 74

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:13316
MeSH 45 D010188
NCIt 51 C84316
SNOMED-CT 69 47367009
ICD10 34 K86.81
UMLS 74 C0267963
Sources

Summaries for Exocrine Pancreatic Insufficiency

About this section
MalaCards based summary : Exocrine Pancreatic Insufficiency is related to johanson-blizzard syndrome and pancreatic agenesis 1. An important gene associated with Exocrine Pancreatic Insufficiency is COX4I2 (Cytochrome C Oxidase Subunit 4I2), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Gastric acid production. The drugs Pancrelipase and Nitazoxanide have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, testes and pancreas, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 77 Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of... more...

Sources

Related Diseases for Exocrine Pancreatic Insufficiency

About this section

Diseases related to Exocrine Pancreatic Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 johanson-blizzard syndrome 32.6 CFTR UBR1
2 pancreatic agenesis 1 30.6 CFTR PDX1 PNLIP SCT SPINK1
3 cystic fibrosis 30.1 CFTR PNLIP SPINK1
4 duodenal atresia 30.1 CFTR SCT
5 diabetes mellitus, permanent neonatal 30.1 PDX1 PTF1A
6 neonatal diabetes mellitus 29.8 PDX1 PTF1A
7 pancreatitis 29.5 CCK CFTR PNLIP SCT SPINK1
8 steatorrhea 29.5 CCK CFTR PNLIP SCT
9 acute pancreatitis 28.7 CCK CFTR PNLIP SCT SPINK1
10 exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis 12.9
11 shwachman-diamond syndrome 1 11.9
12 pancreatic insufficiency, combined exocrine 11.4
13 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 11.3
14 pancreatic agenesis 2 11.3
15 diabetes mellitus 10.6
16 pancreatic agenesis 10.3 PDX1 PTF1A
17 celiac disease 1 10.2
18 pyle disease 10.1
19 neutropenia 10.1
20 somatostatinoma 10.1
21 ichthyosis 10.1
22 dysostosis 10.1
23 cutis laxa 10.1
24 dwarfism 10.1
25 biliary dyskinesia 10.1 CCK SCT
26 duodenogastric reflux 10.1 CCK SCT
27 pancreatic cholera 10.1 CCK SCT
28 duodenal gastrinoma 10.1 CCK SCT
29 space motion sickness 10.1 CCK SCT
30 alzheimer disease 10.0
31 blood group system, landsteiner-wiener 10.0
32 ichthyosis bullosa of siemens 10.0
33 pancreas, annular 10.0
34 enterokinase deficiency 10.0
35 netherton syndrome 10.0
36 fabry disease 10.0
37 calvarial hyperostosis 10.0
38 anorexia nervosa 10.0
39 shwachman-diamond syndrome 2 10.0
40 autoimmune hepatitis 10.0
41 diabetic neuropathy 10.0
42 ectodermal dysplasia 10.0
43 hepatitis 10.0
44 liver disease 10.0
45 pancreas adenocarcinoma 10.0
46 tropical sprue 10.0
47 respiratory failure 10.0
48 pancytopenia 10.0
49 hyperostosis 10.0
50 adenocarcinoma 10.0

Graphical network of the top 20 diseases related to Exocrine Pancreatic Insufficiency:



Diseases related to Exocrine Pancreatic Insufficiency
Sources

Symptoms & Phenotypes for Exocrine Pancreatic Insufficiency

About this section

MGI Mouse Phenotypes related to Exocrine Pancreatic Insufficiency:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 CFTR PDX1 PNLIP PTF1A SPINK1 UBR1
2 endocrine/exocrine gland MP:0005379 9.73 CCK CFTR PDX1 PTF1A SPINK1 UBR1
3 growth/size/body region MP:0005378 9.7 CFTR COX4I2 PDX1 PNLIP PTF1A SPINK1
4 homeostasis/metabolism MP:0005376 9.56 CCK CFTR COX4I2 PDX1 PNLIP PTF1A
5 no phenotypic analysis MP:0003012 9.02 CCK CFTR PDX1 PTF1A SPINK1
Sources

Drugs & Therapeutics for Exocrine Pancreatic Insufficiency

About this section

Drugs for Exocrine Pancreatic Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53608-75-6
2
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
3 pancreatin Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Antiparasitic Agents Phase 4
6 Bifidobacterium Phase 4
7 Anti-Infective Agents Phase 4,Phase 2,Phase 3
8
Omeprazole Approved, Investigational, Vet_approved Phase 3,Phase 2 73590-58-6 4594
9
Vidarabine Approved, Investigational Phase 2, Phase 3,Phase 3 24356-66-9 21704 32326
10
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1 55-98-1 2478
11
Fludarabine Approved Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
12
alemtuzumab Approved, Investigational Phase 2, Phase 3,Not Applicable,Early Phase 1 216503-57-0
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Not Applicable 50-18-0, 6055-19-2 2907
14
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
15
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
16
Ivacaftor Approved Phase 3 873054-44-5 16220172
17 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2,Not Applicable
18 Proton Pump Inhibitors Phase 3,Phase 2
19 Antacids Phase 3,Phase 2
20 Anti-Ulcer Agents Phase 3,Phase 2
21 Antilymphocyte Serum Phase 2, Phase 3,Phase 3,Not Applicable
22 Alkylating Agents Phase 2, Phase 3,Phase 3
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
24 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
25 Antimetabolites Phase 2, Phase 3,Phase 3
26 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
27 Antiviral Agents Phase 2, Phase 3,Phase 3
28 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 3
29 Antirheumatic Agents Phase 2, Phase 3,Phase 1
30 Adjuvants, Immunologic Phase 2, Phase 3
31 Antineoplastic Agents, Immunological Phase 2, Phase 3
32
Secretin Approved Phase 2,Not Applicable 108153-74-8
33
tannic acid Approved Phase 2 1401-55-4
34
Zinc Approved, Investigational Phase 2 7440-66-6 32051
35
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
36
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
37
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
38
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
39
Cefazolin Approved Phase 2 25953-19-9 33255 656510
40
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
41
Dalteparin Approved Phase 2 9005-49-6
42
Melphalan Approved Phase 2,Early Phase 1 148-82-3 460612 4053
43
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
45
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
46
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
47
leucovorin Approved Phase 2 58-05-9 143 6006
48
Choline Approved, Nutraceutical Phase 2 62-49-7 305
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT01327703 Phase 4 Panzytrat® 25,000;Kreon® 25,000
2 PR-018: An Open-Label, Safety Extension of Study PR-011 Completed NCT01131507 Phase 4 EUR-1008 (APT-1008)
3 A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age Completed NCT01100606 Phase 4 EUR-1008 (APT-1008);EUR-1008 (APT-1008)
4 EASY: Extended Access to Sollpura Over Years Completed NCT02823964 Phase 4 Liprotamase
5 Creon After Pancreatic Surgery Completed NCT00535756 Phase 4 Creon;Placebo
6 Enzyme Suppletion in Exocrine Pancreatic Dysfunction Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
7 Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Completed NCT00572975 Phase 4
8 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
9 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
10 HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery Enrolling by invitation NCT03642093 Phase 4
11 A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI) Not yet recruiting NCT03859869 Phase 4 Pancrelipase;Placebo
12 A Study to Compare US Marketed Pancrelipase Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis. Not yet recruiting NCT03924947 Phase 4 Pancrelipase
13 Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
14 Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control Terminated NCT00744250 Phase 4 Pancrelipase
15 A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Withdrawn NCT02009410 Phase 4 Creon;Creon 25000 matching Placebo
16 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
17 Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Unknown status NCT01012908 Phase 2, Phase 3
18 Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Completed NCT01641393 Phase 3 EUR-1008 25,000 Units;Kreon 25,000 Units
19 Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00981214 Phase 3 EUR-1008 (APT-1008)
20 Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Completed NCT00449878 Phase 3 Liprotamase;Placebo
21 A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Completed NCT00662675 Phase 3 Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21
22 Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Completed NCT00297167 Phase 3 EUR-1008 (APT-1008);Placebo;Placebo;EUR-1008 (APT-1008)
23 A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) Completed NCT00788593 Phase 3 Placebo;EUR-1008 (APT-1008) High Dose;EUR-1008 (APT-1008) Low Dose
24 A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency Completed NCT00400842 Phase 3 SA-001;SA-001;Placebo
25 Open-Label Phase III Long-Term Safety Trial of Liprotamase Completed NCT00449904 Phase 3 Liprotamase
26 Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Completed NCT00408317 Phase 3 Ultrase® MT20;Placebo
27 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT00775528 Phase 3 Pancrelipase Delayed Release
28 SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis Completed NCT02734810 Phase 3 Liprotamase Powder for Oral Solution
29 Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF) Completed NCT00690820 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
30 Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency Completed NCT01747330 Phase 3 Pancreatin
31 A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency Completed NCT00401076 Phase 3 SA-001
32 Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis Completed NCT00705978 Phase 3 Pancreatin;Placebo
33 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy Completed NCT00414908 Phase 3 Pancrelipase delayed release capsule;Placebo Comparator
34 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
35 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02137382 Phase 3 Creon®;Creon N
36 Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Completed NCT00513682 Phase 3 Ultrase® MT20
37 Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT00510484 Phase 3 Pancrelipase Delayed Release;Placebo Comparator
38 Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Completed NCT00559364 Phase 3 Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole
39 Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis Completed NCT00432861 Phase 3 PANCRECARB® (pancrelipase);Placebo
40 Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) Completed NCT00880100 Phase 3 Ultrase® MT12
41 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
42 Equivalence Study to Compare Two Strengths of Creon in China Recruiting NCT03450772 Phase 3 Creon® 25000;Creon® 10000
43 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment Active, not recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
44 Stem Cell Transplant for Hemoglobinopathy Active, not recruiting NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
45 Phase III ALTU-135 CP Safety Trial Terminated NCT00500084 Phase 3 Liprotamase
46 A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation Terminated NCT02742519 Phase 3 ivacaftor;Placebo
47 Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs Withdrawn NCT01228643 Phase 3
48 Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT01710644 Phase 1, Phase 2 Burlulipase;Placebo (Caramel in sterile water)
49 Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis Completed NCT02415959 Phase 2 Creon IR;Creon® (DR/GR)
50 Oral TheraCLECâ„¢ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Completed NCT00095732 Phase 2 Liprotamase;Placebo

Search NIH Clinical Center for Exocrine Pancreatic Insufficiency

Cochrane evidence based reviews: exocrine pancreatic insufficiency

Sources

Genetic Tests for Exocrine Pancreatic Insufficiency

About this section
Sources

Anatomical Context for Exocrine Pancreatic Insufficiency

About this section

MalaCards organs/tissues related to Exocrine Pancreatic Insufficiency:

42
Testes, Pancreas, Bone, Liver, Bone Marrow, Small Intestine, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Exocrine Pancreatic Insufficiency:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells Affected by disease, potential therapeutic candidate
Sources

Publications for Exocrine Pancreatic Insufficiency

About this section

Articles related to Exocrine Pancreatic Insufficiency:

(show top 50) (show all 305)
# Title Authors Year
1
Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: True Association or EPIphenomenon? ( 31076987 )
2019
2
Serum cobalamin and folate as prognostic factors in canine exocrine pancreatic insufficiency: An observational cohort study of 299 dogs. ( 30606434 )
2019
3
Transient Exocrine Pancreatic Insufficiency in Children: An Existing Entity? ( 30633105 )
2019
4
Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer Is Not Severe. ( 30650423 )
2019
5
Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management: a review of the literature and a proposal for treatment by the Italian Association for the Study of the Pancreas and the Italian Society on Alcohol. ( 30938130 )
2019
6
Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. ( 30962702 )
2019
7
Correlation Between the Standard Pancreatic Elastase-1 Enzyme-Linked Immunosorbent Assay Test and the New, Rapid Fecal Pancreatic Elastase-1 Test for Diagnosing Exocrine Pancreatic Insufficiency. ( 30973468 )
2019
8
Optimizing Clinical and Cost Outcomes for Patients on Enteral Nutrition Support for Treatment of Exocrine Pancreatic Insufficiency: Proceedings from an Expert Advisory Board Meeting. ( 31066618 )
2019
9
Bruising as the first sign of exocrine pancreatic insufficiency in infancy. ( 31086851 )
2019
10
Cutis laxa, exocrine pancreatic insufficiency and altered cellular metabolomics as additional symptoms in a new patient with ATP6AP1-CDG. ( 29396028 )
2018
11
Exocrine pancreatic insufficiency is common in people living with HIV on effective antiretroviral therapy. ( 28838283 )
2018
12
Prevalence of exocrine pancreatic insufficiency in patients with chronic pancreatitis without follow-up. PANCR-EVOL Study. ( 28935122 )
2018
13
Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis. ( 29374614 )
2018
14
Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. ( 29405509 )
2018
15
Pancreatic-like enzymes of microbial origin restore growth and normalize lipid absorption in a pig model with exocrine pancreatic insufficiency. ( 29593816 )
2018
16
Transient Exocrine Pancreatic Insufficiency: First Report of an Unrecognized Complication of Cytoreductive Surgery and HIPEC. ( 29599360 )
2018
17
Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: do we need to treat it? A systematic review. ( 29779830 )
2018
18
Diagnosis and Management of Exocrine Pancreatic Insufficiency. ( 30027527 )
2018
19
Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences. ( 30074926 )
2018
20
Serum concentrations of lipid-soluble vitamins in dogs with exocrine pancreatic insufficiency treated with pancreatic enzymes. ( 30133868 )
2018
21
Evaluation of density gradient ultracentrifugation serum lipoprotein profiles in healthy dogs and dogs with exocrine pancreatic insufficiency. ( 30175670 )
2018
22
Randomized placebo controlled clinical trial of an enteric coated micro-pelleted formulation of a pancreatic enzyme supplement in dogs with exocrine pancreatic insufficiency. ( 30221800 )
2018
23
Clinical Characteristics and Genetic Causes of Infantile Exocrine Pancreatic Insufficiency in Chinese Patients: Study From a Tertiary Care Center. ( 30308536 )
2018
24
Endocrine and exocrine pancreatic insufficiency after acute pancreatitis: long-term follow-up study. ( 29078749 )
2017
25
PDX1 Gene Mutation with Permanent Neonatal Diabetes Mellitus with Annular Pancreas, Duodenal Atresia, Hypoplastic Gall Bladder and Exocrine Pancreatic Insufficiency. ( 29317564 )
2017
26
Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy. ( 27864215 )
2017
27
Practical guide to exocrine pancreatic insufficiency - Breaking the myths. ( 28183317 )
2017
28
Black-Box Gastrointestinal Tract-Needs and  Prospects of Gaining Insights of Fate of Fat, Protein,  and Starch in Case of Exocrine Pancreatic  Insufficiency by Using Fistulated Pigs. ( 28212351 )
2017
29
The fecal microbiome of dogs with exocrine pancreatic insufficiency. ( 28223257 )
2017
30
Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-Mixed Triglyceride Breath Test versus Fecal Elastase. ( 28291656 )
2017
31
Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. ( 28315875 )
2017
32
Mutations in EFL1, an SBDS partner, are associated with infantile pancytopenia, exocrine pancreatic insufficiency and skeletal anomalies in aShwachman-Diamond like syndrome. ( 28331068 )
2017
33
Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-Mixed Triglyceride Breath Test versus Fecal Elastase: Methodological issues. ( 28462863 )
2017
34
Alzheimer's disease and other neurodegenerative diseases may be due to nutritional deficiencies secondary to unrecognized exocrine pancreatic insufficiency. ( 28478840 )
2017
35
Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency). ( 28554722 )
2017
36
Response to "Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-mixed Triglyceride Breath Test versus Fecal Elastase: Methodological issues". ( 28566224 )
2017
37
Oxalate nephropathy presenting in exocrine pancreatic insufficiency. ( 28685941 )
2017
38
A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. ( 28727474 )
2017
39
Options for addressing exocrine pancreatic insufficiency in patients receiving enteral nutrition supplementation. ( 28727476 )
2017
40
Severe infantile isolated exocrine pancreatic insufficiency caused by the complete functional loss of the SPINK1 gene. ( 28945313 )
2017
41
Less common etiologies of exocrine pancreatic insufficiency. ( 29093615 )
2017
42
Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis. ( 29212278 )
2017
43
Challenges and Updates in the Management of Exocrine Pancreatic Insufficiency. ( 26658035 )
2016
44
Exocrine Pancreatic Insufficiency. ( 26834230 )
2016
45
Rapid maxillary expansion in a pediatric patient with exocrine pancreatic insufficiency. ( 26943081 )
2016
46
Exocrine Pancreatic Insufficiency after Roux-en-Y gastric bypass. ( 26965152 )
2016
47
Exocrine pancreatic insufficiency in a child with Netherton syndrome. ( 26986028 )
2016
48
Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. ( 27045859 )
2016
49
Both Exocrine Pancreatic Insufficiency and Signs of Pancreatic Inflammation Are Prevalent in Children with Complicated Severe Acute Malnutrition: An Observational Study. ( 27178623 )
2016
50
Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. ( 27297209 )
2016
Sources

Variations for Exocrine Pancreatic Insufficiency

About this section
Sources

Expression for Exocrine Pancreatic Insufficiency

About this section
Search GEO for disease gene expression data for Exocrine Pancreatic Insufficiency.
Sources

Pathways for Exocrine Pancreatic Insufficiency

About this section

Pathways related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.26 CFTR PDX1 PTF1A
2
Gastric acid production 1
9.47 CCK SCT
Sources

GO Terms for Exocrine Pancreatic Insufficiency

About this section

Biological processes related to Exocrine Pancreatic Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 9.32 COX4I2 PDX1
2 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.26 CFTR PDX1
3 pancreas development GO:0031016 9.16 PDX1 PTF1A
4 sperm capacitation GO:0048240 8.96 CFTR SPINK1
5 exocrine pancreas development GO:0031017 8.62 PDX1 PTF1A
Sources

Sources for Exocrine Pancreatic Insufficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....